AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts
- 29 August 2023
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 134, 107376
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- C/EBPα deregulation as a paradigm for leukemogenesisLeukemia, 2017
- Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid MalignanciesArchives of Pathology & Laboratory Medicine, 2017
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- The multifaceted functions of C/EBPα in normal and malignant haematopoiesisLeukemia, 2015
- Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsBlood, 2015
- Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemiaHaematologica, 2010
- Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 MutationsJournal of Clinical Oncology, 2010
- Systematic analysis of short internal indels and their impact on protein foldingBMC Structural Biology, 2010
- Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcomeBlood, 2009
- Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosisBritish Journal of Cancer, 2009